EverImmune is a spin-off biotech. Cie from Gustave Roussy Transfert, created in 2016 and devoted to treating cancer patients with live biotherapeutic products (LBP) i.e immunogenic commensals that are called “Oncobax®” for oral adjuvants to anticancer immunotherapy. EverImmune harness the gut microbiota for the development of a revolutionary theranostic approach combining diagnostic and therapeutic technologies that will ensure the benefit of ICBs in cancer patients.
39 RUE CAMILLE DESMOULINS, 94800 VILLEJUIF
Targeted indications : Lung cancer